Akadeum Life Sciences files to raise $3.4M Series C for microbubble cell separation
What's the deal? Akadeum Life Sciences has filed a notice with the Securities and Exchange Commission to raise up to $3,427,230 in a Series C round. The filing, made under Regulation D, lists chief financial officer James Militello as the contact.
What's the endgame? The biotechnology company develops microbubble-based cell separation technologies for research, diagnostic, and therapeutic markets. Its buoyant microbubble platform enriches cells while preserving their health and physiology.
Why it matters? Akadeum sells cell separation products and kits for cell therapy manufacturing, purification, and immunology research, including GMP-grade and clinical-ready tools. It says the technology can cut overall cell therapy manufacturing costs by up to 40%.
The signal: Cell and gene therapies remain expensive to produce at scale, and suppliers pitching efficiency gains have drawn steady investor interest. Akadeum's raise reflects continued demand for tools that make cell therapy translation faster and cheaper.
Read more: intelligence360.news
Image credit: Generated with Gemini
